Literature DB >> 21229280

Vancomycin MIC creep in MRSA blood culture isolates from Germany: a regional problem?

J Kehrmann1, M Kaase, F Szabados, S G Gatermann, J Buer, P-M Rath, J Steinmann.   

Abstract

The aim of this study was to assess the vancomycin MIC distribution for MRSA blood culture isolates over a period of six years in Germany. The study examined 287 MRSA isolates from blood cultures collected at several hospitals in two German cities between 2004 and 2009. The vancomycin MIC was determined by Etest. Genotypic features of the MRSA strains with vancomycin MIC ≥ 1 mg/L were determined by semiautomated repetitive-sequence-based polymerase chain reaction. The range of vancomycin MIC as determined by Etest was 0.25 to 2.0 mg/L. The geometric mean MIC increased by 1.34-fold in city A over the study period (p < 0.05), but there was no meaningful change in city B (a 1.09-fold increase, p > 0.05). Furthermore, in city A a shift in vancomycin MICs occurred as an increase in the percentage of isolates with MIC ≥ 1 mg/L from period one (2004-2006) to period two (2007-2009) (p < 0.0001). Typing results showed that in city A a single clone was predominant (55% of the creep isolates). In this study, the creep phenomenon seems to be a regional problem. We suggest that all hospitals should monitor their local status of elevated vancomycin MICs in invasive MRSA isolates.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21229280     DOI: 10.1007/s10096-010-1140-7

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  36 in total

1.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

Authors:  K Hiramatsu; H Hanaki; T Ino; K Yabuta; T Oguri; F C Tenover
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

Review 2.  Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections.

Authors:  P A Moise; J J Schentag
Journal:  Int J Antimicrob Agents       Date:  2000-11       Impact factor: 5.283

3.  Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.

Authors:  Kerry L LaPlante; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

4.  Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002).

Authors:  Douglas J Biedenbach; Gary J Moet; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2004-09       Impact factor: 2.803

5.  Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin.

Authors:  T P Lodise; J Graves; A Evans; E Graffunder; M Helmecke; B M Lomaestro; K Stellrecht
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

6.  Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.

Authors:  Richard G Wunderink; Jordi Rello; Sue K Cammarata; Rodney V Croos-Dabrera; Marin H Kollef
Journal:  Chest       Date:  2003-11       Impact factor: 9.410

7.  Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  George Sakoulas; Pamela A Moise-Broder; Jerome Schentag; Alan Forrest; Robert C Moellering; George M Eliopoulos
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

8.  Daptomycin in the treatment of bacteremia.

Authors:  George Sakoulas; Yoav Golan; Kenneth C Lamp; Lawrence V Friedrich; Rene Russo
Journal:  Am J Med       Date:  2007-10       Impact factor: 4.965

9.  Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage.

Authors:  Juan-Ignacio Alós; Ana García-Cañas; Paloma García-Hierro; Francisco Rodríguez-Salvanés
Journal:  J Antimicrob Chemother       Date:  2008-06-13       Impact factor: 5.790

10.  Staphylococcus aureus bacteremia, Europe.

Authors:  Edine W Tiemersma; Dominique L Monnet; Nienke Bruinsma; Robert Skov; Jos C M Monen; Hajo Grundmann
Journal:  Emerg Infect Dis       Date:  2005-11       Impact factor: 6.883

View more
  14 in total

1.  Is vancomycin MIC "creep" method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010.

Authors:  B Edwards; K Milne; T Lawes; I Cook; A Robb; I M Gould
Journal:  J Clin Microbiol       Date:  2011-11-30       Impact factor: 5.948

Review 2.  Bloodstream infections in the Intensive Care Unit.

Authors:  Matteo Bassetti; Elda Righi; Alessia Carnelutti
Journal:  Virulence       Date:  2016-01-13       Impact factor: 5.882

3.  Effects of storage on vancomycin and daptomycin MIC in susceptible blood isolates of methicillin-resistant Staphylococcus aureus.

Authors:  Franziska Ludwig; Becky Edwards; Timothy Lawes; Ian M Gould
Journal:  J Clin Microbiol       Date:  2012-08-01       Impact factor: 5.948

Review 4.  Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections in Children: a Reappraisal of Vancomycin.

Authors:  Roopali Sharma; Margaret R Hammerschlag
Journal:  Curr Infect Dis Rep       Date:  2019-09-05       Impact factor: 3.725

5.  Vancomycin: the tale of the vanquisher and the pyrrhic victory.

Authors:  An S De Vriese; Stefaan J Vandecasteele
Journal:  Perit Dial Int       Date:  2014 Mar-Apr       Impact factor: 1.756

6.  An Unusual Occurrence of Methicillin Resistant Staphylococcal Endocarditis with Vancomycin Creep Phenomenon - A Therapeutic Challenge.

Authors:  S Sneha; Shanthan Venishetty; Shubha Seshadri; M Sudhakar Rao; Chiranjay Mukhopadhyay
Journal:  J Clin Diagn Res       Date:  2016-12-01

Review 7.  A current perspective on daptomycin for the clinical microbiologist.

Authors:  Romney M Humphries; Simon Pollett; George Sakoulas
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

8.  Decreased Vancomycin MICs among Methicillin-Resistant Staphylococcus aureus Clinical Isolates at a Chinese Tertiary Hospital over a 12-year Period.

Authors:  Chaohui Lu; Yinjuan Guo; Shanshan Wang; Zhengzheng Wang; Lan Chen; Jinnan Lv; Xiuqin Qi; Zengqiang Chen; Lizhong Han; Xueqing Zhang; Liangxing Wang; Fangyou Yu
Journal:  Front Microbiol       Date:  2016-10-27       Impact factor: 5.640

9.  Epidemiology and risk factors of methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci infections in Zhejiang China from 2015 to 2017.

Authors:  Lin Huang; Rong Zhang; Yanyan Hu; Hongwei Zhou; Junmin Cao; Huoyang Lv; Shi Chen; Shibiao Ding; Gongxiang Chen
Journal:  Antimicrob Resist Infect Control       Date:  2019-05-30       Impact factor: 4.887

10.  Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey.

Authors:  Banu Sancak; Server Yagci; Deniz Gür; Zeynep Gülay; Dilara Ogunc; Güner Söyletir; Ata Nevzat Yalcin; Devrim Oztürk Dündar; Ayşe Willke Topçu; Filiz Aksit; Gaye Usluer; Cüneyt Ozakin; Halis Akalin; Mutlu Hayran; Volkan Korten
Journal:  BMC Infect Dis       Date:  2013-12-10       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.